IDEXX Laboratories Inc (IDXX)vsQiagen NV (QGEN)
IDXX
IDEXX Laboratories Inc
$575.72
+0.97%
HEALTHCARE · Cap: $45.53B
QGEN
Qiagen NV
$40.63
+2.14%
HEALTHCARE · Cap: $8.20B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 106% more annual revenue ($4.30B vs $2.09B). IDXX leads profitability with a 24.6% profit margin vs 20.3%. QGEN appears more attractively valued with a PEG of 1.00. QGEN earns a higher WallStSmart Score of 69/100 (B-).
IDXX
Buy61
out of 100
Grade: C+
QGEN
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.2%
Fair Value
$462.85
Current Price
$575.72
$112.87 premium
Margin of Safety
+40.2%
Fair Value
$85.35
Current Price
$40.63
$44.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.8%
Keeps 20 of every $100 in revenue as profit
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 27.4%
Earnings expanding 21.9% YoY
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
3.7% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : QGEN
The strongest argument for QGEN centers on Profit Margin, PEG Ratio, Price/Book. Profitability is solid with margins at 20.3% and operating margin at 27.4%. PEG of 1.00 suggests the stock is reasonably priced for its growth.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth.
Key Dynamics to Monitor
IDXX profiles as a mature stock while QGEN is a value play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.70 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
QGEN scores higher overall (69/100 vs 61/100), backed by strong 20.3% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?